Cell MedX (OTCMKTS:CMXC) Trading 11.7% Higher – Still a Buy?
by Doug Wharley · The Cerbat GemCell MedX Corp. (OTCMKTS:CMXC – Get Free Report)’s share price traded up 11.7% on Thursday . The company traded as high as $0.35 and last traded at $0.3352. 12,802 shares were traded during trading, a decline of 37% from the average session volume of 20,342 shares. The stock had previously closed at $0.3001.
Cell MedX Stock Up 11.7%
The company’s 50 day simple moving average is $0.37 and its 200-day simple moving average is $0.37.
About Cell MedX
Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney functions in the United States. The company develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual.